#Switzerland #Basel #Cube Biotech #Allegria Therapeutics #MastCURe

Significant Funding for MastCURe's Novel Therapies

MastCURe, a prominent research consortium based in Basel, Switzerland, has been the recipient of €1.3 million in funding granted by the Eureka Eurostars program. This funding aims to propel the development of targeted therapies for chronic urticaria, a condition characterized by debilitating skin reactions caused by abnormal mast cell activity. Until now, millions of individuals worldwide have grappled with this condition, revealing a pressing need for effective treatment options.

This endeavor is a collaboration that brings together three key players: Allegria Therapeutics, Cube Biotech, and the Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP). The collaboration ultimately seeks to revolutionize how chronic urticaria is tackled by leveraging innovative approaches to directly address the mechanisms driving this skin affliction.

The Research Consortium Unveils Its Strategy

At the heart of MastCURe’s approach lies a method that selectively targets and resolves the aberrant activation of mast cells, the primary culprits in chronic urticaria. The recent Eurostars funding earned by the consortium will significantly advance their collaborative research and development projects, allowing them to expedite the journey toward the introduction of completely new first-in-class therapeutics designed to enhance the quality of life for affected patients.

Jörg Scheffel, Ph.D., the Head of Drug and Solution Discovery at Fraunhofer ITMP-IA, articulated the urgency behind this research, noting that chronic urticaria severely impairs patients’ quality of life, often leaving many under-treated.

"Despite additional therapies becoming available, many patients still suffer from relentless symptoms that interfere with their daily lives. This funding enables us to accelerate our groundbreaking research, getting us closer to offering a novel therapeutic approach that truly addresses their needs," he said.

Leveraging Advanced Technology for Better Insights

Allegria Therapeutics leads this research consortium and specializes in developing innovative therapies aimed at mast cell-mediated diseases. The consortium is enhanced by Cube Biotech's unique NativeMP™ technology, which allows for the structural determination of mast cell-related membrane proteins while maintaining their essential biological features.

Barbara Maertens, Ph.D., COO and Co-Founder of Cube Biotech, expressed that their collaboration aims to deepen the understanding of mast cell-related proteins, setting the stage for the development of transformative therapeutic strategies tailored for those battling chronic urticaria.

Furthermore, Fraunhofer ITMP-IA's contribution involves validating findings using skin-derived mast cells and ex vivo skin tissue models, which will greatly inform the effectiveness of proposed therapies.

Significance of the Therapeutics Domain

Chronic urticaria is substantially detrimental, affecting over 60 million individuals globally. Characterized by itchy welts and significant swelling triggered by mast cells releasing histamine and other inflammatory substances, this condition currently lacks apt solutions. Common treatments like antihistamines or IgE-directed therapies frequently fall short of providing satisfactory relief for many patients.

With the support of Eurostars, MastCURe's initiative signifies a hopeful leap towards a more scientific and targeted treatment modality. Maria van Dongen, Ph.D., CEO and Co-Founder of Allegria Therapeutics stated, "Our precision therapies will allow us to hone in on specific cell types and mechanisms, altering the underlying disease biology with increased efficacy and improved safety profiles. We’re incredibly grateful for the funding that bolsters our mission to furnish advanced treatment options for patients dealing with various allergic and inflammatory disorders."

Company Backgrounds

Founded in 2023 by Forty51 Ventures, Allegria Therapeutics is at the forefront of redefining therapeutic options for mast cell-mediated inflammatory diseases. Cube Biotech, based in Germany, specializes in advanced membrane protein production and characterization. Meanwhile, the Fraunhofer Institute is recognized for its leading research in allergic and immunological diseases, establishing a promising landscape for future breakthroughs in treatments for chronic urticaria.

Looking Ahead

As practitioners, researchers, and patients look forward to innovative breakthroughs, the MastCURe consortium stands poised to pave the way towards effective solutions that can profoundly transform treatment protocols for chronic urticaria. Their work not only emphasizes the potential of focused therapeutic development but also reflects a broader commitment to tackling long-standing medical challenges in allergy and immunology.